Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:oxazolidinone
gptkb:antibiotic |
| gptkbp:activeIn |
gptkb:methicillin-resistant_Staphylococcus_aureus
Gram-positive bacteria |
| gptkbp:actsOn |
bacterial 50S ribosomal subunit
|
| gptkbp:administeredBy |
oral
intravenous |
| gptkbp:approvedBy |
gptkb:FDA
2014 |
| gptkbp:ATCCode |
J01XX11
|
| gptkbp:CASNumber |
856867-55-5
|
| gptkbp:developedBy |
gptkb:Cubist_Pharmaceuticals
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:eliminationHalfLife |
12 hours
|
| gptkbp:hasMolecularFormula |
C17H15FN6O6P
|
| https://www.w3.org/2000/01/rdf-schema#label |
tedizolid phosphate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Sivextro
|
| gptkbp:mechanismOfAction |
protein synthesis inhibitor
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prodrugOf |
gptkb:tedizolid
|
| gptkbp:PubChem_CID |
24873441
DB09040 |
| gptkbp:sideEffect |
nausea
vomiting diarrhea headache |
| gptkbp:UNII |
8N0O0I06Z6
|
| gptkbp:usedFor |
acute bacterial skin and skin structure infections
|
| gptkbp:bfsParent |
gptkb:Sivextro
|
| gptkbp:bfsLayer |
6
|